Abstract
Objective: The present study was conducted to assess the efficacy and safety of bilastine 20 mgand compare the results with that of levocetirizine 5 mg in the treatment of allergicrhinoconjunctivitis. Material and Methods: It was a prospective study conducted in theDepartment of Ophthalmology and Department of Otorhinolaryngology at a tertiary institute ofsouthern Rajasthan, India during the period of 6 months from September 2019 to February 2020.100 patients of chronic allergic rhinoconjunctivitis were included in the study, of which 50 weretreated with Bilastine 20 mg, and the rest 50 patients were treated with levocetirizine 5 mg. Theprimary assessment was done by calculating the total symptom score (TSS) before and after the 7thand 14th post-treatment day. Results: The age of the patients ranges from 10 years to 65 yearswith a mean age of 32±5.2 years. The primary efficacy parameter for assessment was a reduction intotal symptom score (TSS). Both bilastine 20 mg and levocetirizine 5 mg significantly reduced theTSS on the 7th and 14th post-treatment days (p-value< 0.001). There was no significant differencebetween TSS of bilastine and levocetirizine after 7 days (p-value= 0.41) and after 14 days treatment(p-value= 0.68). Adverse events were reported by 10% of patients in the bilastine group and by38% of patients in the levocetirizine group. Conclusion: Bilastine is a selective H1 antihistaminewith good efficacy and excellent safety profile and it is highly recommended to use it as a first-linetreatment for allergic rhinoconjunctivitis.
Highlights
Allergic rhinoconjunctivitis is a common problem worldwide and its incidences are increasing day by day [1]
The primary efficacy parameter for assessment was a reduction in total symptom score (TSS)
The present study was a comparative analysis of efficacy and safety between bilastine 20 mg and levocetirizine 5 mg for the treatment of chronic allergic rhinoconjunctivitis
Summary
Allergic rhinoconjunctivitis is a common problem worldwide and its incidences are increasing day by day [1]. Data suggest that approximately 10-40% of the global population is affected by allergic rhinoconjunctivitis [2,3,4,5]. Allergic diseases impose a negative impact on a patient’s physical, social, and psychological functioning with an adverse effect on a person’s work capacity and quality of life. H1 antihistamines are used as first-line treatment to treat allergic rhinoconjunctivitis for a long time [68]. First-generation H1 antihistamines have many side effects including anticholinergic effects, sedation, and interaction with alcohol and other drugs. Second-generation H1 antihistamines are free of anticholinergic effects, cause no sedation, and do not interact with alcohol or other drugs and are used as first-line treatment for allergic diseases
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Tropical Journal of Ophthalmology and Otolaryngology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
